Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EU invests 10.7 million Euro on EICOSANOX - a top-ranking project led from Karolinska Institutet

14.02.2005


A decision has now been taken on the grant that the EU’s Sixth Framework Programme is to provide for EICOSANOX, a major research project coordinated by Karolinska Institutet’s Professor Jesper Z. Haeggström. The project, which ranked highest in its category, is an Integrated Project (IP) and is to be allocated research funding of 10.7 million euro over the course of five years. A total of 15 research groups from six European nations will be merged into a very large multi-disciplinary consortium, including a team from Canada and two biotech companies. The research is focused on prostaglandins, leukotrienes and nitric oxide, all of which are central to widespread diseases like cardiovascular disorders, atherosclerosis, dementia and cancer.



Several components of the project have given the EU cause to rank this project high:

• Relevance - it concerns important disease groups that are responsible for the majority of all deaths in Europe.
• European expertise – there is already unique expertise in Europe equal to the best in the USA and Japan.


• It has clear commercial potential, something which is given priority in the EU’s Sixth Framework Programme.

The research examines the enzyme systems that govern the formation of certain signal substances in the body, particularly derivatives of arachidonic acid. These substances control the course of events during inflammation and fever as well as blood coagulation and cellular growth. They are therefore of significance to several major disease areas, such as cardiovascular diseases, dementia and cancer. If scientists learn how to control these signal substances, they may be able to find suitable therapies. The annual global sales of drugs in these therapeutic areas have been estimated to more than 100 million Euro.

“I’ve hand-picked every single group involved,” says Professor Jesper Z. Haeggström, who is leading the consortium from Karolinska Institutet. “All of them are at the forefront of their specialist research fields.”

The consortium brings together research groups from Sweden, Germany, Italy, United Kingdom, Ireland and Spain, with three different specialisations: COX, LOX and NOS, abbreviations that stand for three different enzyme systems and their products. The systems and their functions are intimately integrated in the body, and the objective of the project is for the groups to meet and pool their knowledge. One important goal is to identify new genes that are involved in the regulation of COX, LOX and NOS, and that can be used to develop new drugs.

Enzymes of the COX family regulate the formation of prostaglandins from arachidonic acid (a fatty acid). “We block this system every time we take a normal aspirin, and this is also where the controversial COX-2 inhibitors, VIOXX and Celebrex, have their effect,” continues Professor Haeggström.

The second enzyme type, LOX, is necessary for the formation of leukotrienes, which are also derived from arachidonic acid. Important drugs have been produced in this area too, in particular the anti-leukotrienes that are used in the treatment of asthma and allergic hay fever. The third specialisation involves NOS, the enzyme active in the synthesis of nitric oxide, the central role of which has become all the more noted recently. The system is affected, for instance, during nitroglycerine therapy for angina and on the treatment of impotence with the now infamous Viagra.

Apart from four groups at Karolinska Institutet, the network formed through the consortium includes the University of Frankfurt, which has research groups in all three areas. Cardiologists from Italy’s D’Annunzio University are also involved, along with British researchers from the renowned William Harvey Institute and Salvador Moncada, one of the world’s most eminent researchers in the field of nitric oxide. The Canadian group is specialised in animal models for studies of eicosanoids. Two biotech companies, the Swedish Biolipox AB and the Franco-Italian NicOx, are also taking part.

Research into prostaglandins and leukotrienes (also known as eicosanoids) has long been a flagship field of research in Sweden and one in which we have led the world. The substances were discovered at Karolinska Institutet, which earned Sune Bergström and Bengt Samuelsson, together with John R. Vane from England, the Nobel Prize in Physiology or Medicine in 1982.

“Karolinska Institutet has trained many of today’s leading Japanese and American researchers in eicosanoids,” says Professor Haeggström.

The consortium includes four groups from Sweden and Karolinska Institutet:

• Professor Haeggström’s team at the Department of Medical Biochemistry and Biophysics, specialising in preclinical basic research into eicosanoids and the COX and LOX enzyme systems.
• Jon Lundberg’s team at the Department of Physiology and Pharmacology, specialising in nitric oxides and their role in the body’s immune systems.
• Göran K. Hansson’s team at the Department of Medicine at Karolinska University Hospital in Solna, specialising in clinical research into atherosclerosis and vascular inflammation.
• Pär Nordlund’s team, which has recently moved to Karolinska Institutet and the Department of Medical Biochemistry and Biophysics in order to work with determination of protein structures by X-ray crystallography at large scale.

“For us at Karolinska Institutet, this grant provides valuable long-term basic support at a time when national medical research funds have been completely drained,” says Professor Haeggström. “Each one of the four KI groups will receive between 50 000 and 200 000 Euro per year for five years, and we’ll also be getting extra resources for the administration and coordination of the consortium.”

Jesper Z. Haeggström | alfa
Further information:
http://www.mbb.ki.se

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>